drugset / Trial / NCT01762787

Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers

NCT01762787

Phase 1 Completed 40 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindOther

Summary

The purpose of this study is to refine the cantharidin-induced blister assay in healthy volunteers as a model of inflammatory disease. The study is an experimental trial in healthy volunteers in two parts; Part 1 to optimise the model and Part 2 to validate using two anti-inflammatory treatments with different modes of action.

Timeline

Start
2010-08-17
Primary completion
2011-01-14
Completion
2011-01-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 300 mg Oral
Subject Cantharidin Small molecule 0.005 ml Topical
Subject Cantharidin Small molecule 0.025 % Topical
Subject Cantharidin Small molecule 0.5 % Topical
Subject Prednisolone Other / unclassified 30 mg Oral

Indications

No indication recorded.